IDEAYA Biosciences Quarterly Income Statements Chart
Quarterly
|
Annual
IDEAYA Biosciences Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses | |||||||||||||||||||||||||
| research and development | 74,226,000 | 70,886,000 | 140,183,000 | 57,152,000 | 54,533,000 | 42,805,000 | 38,770,000 | 33,701,000 | 29,178,000 | 27,859,000 | 24,713,000 | 22,372,000 | 22,796,000 | 19,656,000 | 16,110,000 | 15,503,000 | 14,979,000 | 11,566,000 | 12,051,000 | 10,025,000 | 8,596,000 | 9,026,000 | 8,541,000 | 8,923,000 | 8,859,000 |
| general and administrative | 14,580,000 | 13,503,000 | 10,955,000 | 9,741,000 | 10,394,000 | 8,212,000 | 7,069,000 | 7,863,000 | 7,075,000 | 6,300,000 | 5,752,000 | 6,667,000 | 5,554,000 | 5,923,000 | 5,221,000 | 5,186,000 | 4,828,000 | 4,816,000 | 3,800,000 | 3,938,000 | 3,994,000 | 3,452,000 | 2,778,000 | 2,700,000 | 2,376,000 |
| total operating expenses | 88,806,000 | 84,389,000 | 151,138,000 | 66,893,000 | 64,927,000 | 51,017,000 | 45,839,000 | 41,564,000 | 36,253,000 | 34,159,000 | 30,465,000 | 29,039,000 | 28,350,000 | 25,579,000 | 21,331,000 | 20,689,000 | 19,807,000 | 16,382,000 | 15,851,000 | 13,963,000 | 12,590,000 | 12,478,000 | 11,319,000 | 11,623,000 | 11,235,000 |
| income from operations | -88,806,000 | -84,389,000 | -144,138,000 | -66,893,000 | -64,927,000 | -51,017,000 | -41,917,000 | -33,526,000 | -32,709,000 | -26,279,000 | -26,443,000 | 660,000 | -22,499,000 | -14,220,000 | -18,369,000 | -11,713,000 | -11,051,000 | -9,135,000 | -5,280,000 | -4,996,000 | -12,590,000 | -12,478,000 | -11,319,000 | -11,623,000 | -11,235,000 |
| yoy | 36.78% | 65.41% | 243.87% | 99.53% | 98.50% | 94.14% | 58.52% | -5179.70% | 45.38% | 84.80% | 43.95% | -105.63% | 103.59% | 55.67% | 247.90% | 134.45% | -12.22% | -26.79% | -53.35% | -57.02% | 12.06% | ||||
| qoq | 5.23% | -41.45% | 115.48% | 3.03% | 27.27% | 21.71% | 25.03% | 2.50% | 24.47% | -0.62% | -4106.52% | -102.93% | 58.22% | -22.59% | 56.83% | 5.99% | 20.97% | 73.01% | 5.68% | -60.32% | 0.90% | 10.24% | -2.62% | 3.45% | |
| operating margin % | -1068.77% | -417.09% | -922.94% | -333.49% | -657.46% | 2.22% | -384.53% | -125.19% | -49.95% | -55.72% | |||||||||||||||
| other income | 2,000 | 6,000 | |||||||||||||||||||||||
| interest income and other income | 11,315,000 | 12,211,000 | 13,826,000 | 15,072,000 | 12,155,000 | 11,445,000 | 7,962,000 | 6,086,000 | 4,783,000 | 2,639,000 | 2,242,000 | 955,000 | 443,000 | 207,000 | 157,000 | 131,000 | 104,000 | 114,000 | 145,000 | 70,000 | 199,000 | 435,000 | |||
| net income | -77,491,000 | -72,178,000 | -130,312,000 | -51,821,000 | -52,772,000 | -39,572,000 | -33,955,000 | -27,440,000 | -27,926,000 | -23,640,000 | -24,201,000 | 1,615,000 | -22,056,000 | -14,013,000 | -18,212,000 | -11,582,000 | -10,947,000 | -9,021,000 | -5,135,000 | -4,926,000 | -12,391,000 | -12,043,000 | -10,781,000 | -10,969,000 | -10,656,000 |
| yoy | 46.84% | 82.40% | 283.78% | 88.85% | 88.97% | 67.39% | 40.30% | -1799.07% | 26.61% | 68.70% | 32.88% | -113.94% | 101.48% | 55.34% | 254.66% | 135.12% | -11.65% | -25.09% | -52.37% | -55.09% | 16.28% | ||||
| qoq | 7.36% | -44.61% | 151.47% | -1.80% | 33.36% | 16.54% | 23.74% | -1.74% | 18.13% | -2.32% | -1598.51% | -107.32% | 57.40% | -23.06% | 57.24% | 5.80% | 21.35% | 75.68% | 4.24% | -60.25% | 2.89% | 11.71% | -1.71% | 2.94% | |
| net income margin % | -865.76% | -341.38% | -787.98% | -300.00% | -601.72% | 5.44% | -376.96% | -123.36% | -48.58% | -54.93% | |||||||||||||||
| unrealized gains on marketable securities | -64,000 | 773,000 | -3,024,000 | 5,252,000 | -493,000 | -1,485,000 | 1,312,000 | 429,000 | 226,000 | ||||||||||||||||
| comprehensive loss | -77,555,000 | -71,405,000 | -133,336,000 | -46,569,000 | -53,265,000 | -41,057,000 | -27,700,000 | -22,174,000 | -22,881,000 | -16,105,000 | -18,874,000 | -11,628,000 | -10,950,000 | -9,028,000 | -5,163,000 | -4,948,000 | -12,334,000 | -12,108,000 | -7,771,250 | -10,928,000 | -10,627,000 | ||||
| net income per common share, basic and diluted | -880 | -820 | -1,550 | -600 | -680 | -530 | -500 | -490 | -570 | -360 | -490 | -310 | -330 | -280 | -140 | -170 | -590 | -590 | |||||||
| weighted-average common shares outstanding, basic and diluted | 88,472,197,000 | 88,356,335,000 | 86,188,510,000 | 77,962,730,000 | 75,108,484,000 | ||||||||||||||||||||
| collaboration revenue | 3,922,000 | 8,038,000 | 3,544,000 | 7,880,000 | 4,022,000 | 29,699,000 | 5,851,000 | 11,359,000 | 2,962,000 | 8,976,000 | 8,756,000 | 7,247,000 | 10,571,000 | 8,967,000 | |||||||||||
| total revenue | 3,922,000 | 8,038,000 | 3,544,000 | 7,880,000 | 4,022,000 | 29,699,000 | 5,851,000 | 11,359,000 | 10,571,000 | 8,967,000 | |||||||||||||||
| yoy | -2.49% | -72.94% | -39.43% | -30.63% | |||||||||||||||||||||
| qoq | -51.21% | 126.81% | -55.03% | 95.92% | -86.46% | 407.59% | -48.49% | 17.89% | |||||||||||||||||
| comprehensive income | -19,221,250 | -27,011,000 | -9,436,000 | 1,242,000 | |||||||||||||||||||||
| net income per common share, basic | -360 | -460 | -220 | 40 | |||||||||||||||||||||
| weighted-average number of common shares outstanding used in computing net income per share, basic | 59,999,449 | 40,301,568 | |||||||||||||||||||||||
| net income per common share, diluted | -0.36 | -0.46 | -0.22 | 0.04 | |||||||||||||||||||||
| weighted-average number of common shares outstanding used in computing net income per share, diluted | 59,999,449 | 41,109,571 | |||||||||||||||||||||||
| weighted-average number of common shares outstanding used in computing net income per share, basic and diluted | 81,678,069 | 57,519,929 | 56,251,130 | 48,370,074 | 41,444,696 | 38,660,971 | 38,591,966 | 35,252,443 | 37,769,910 | 32,854,926 | 31,761,207 | 24,721,775 | 28,396,670 | 21,001,730 | 20,250,549 | ||||||||||
| unrealized losses on marketable securities | 1,466,000 | 1,131,000 | -373,000 | -825,000 | -2,092,000 | ||||||||||||||||||||
| change in unrealized losses on marketable securities | -14,250 | -46,000 | -3,000 | -7,000 | |||||||||||||||||||||
| change in unrealized gains on marketable securities | -28,000 | -22,000 | 57,000 | -65,000 | 27,250 | 41,000 | 29,000 | ||||||||||||||||||
| interest income | 536,000 | 654,000 | 573,000 | ||||||||||||||||||||||
| net income per share | -0.21 | -0.54 | -1.3 | ||||||||||||||||||||||
| weighted-average number of shares outstanding, basic and diluted | 20,158,223 | 8,218,010 | |||||||||||||||||||||||
We provide you with 20 years income statements for IDEAYA Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IDEAYA Biosciences stock. Explore the full financial landscape of IDEAYA Biosciences stock with our expertly curated income statements.
The information provided in this report about IDEAYA Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.